secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001193125-23-012507
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024
--------------------------------------------------------------------------------

- Amendment extends contract term to March 31, 2024 (or later date if agreed).
- Pricing and minimum purchase quantity obligations for Fyarro were updated and revised.
- Agreement covers clinical and commercial manufacturing of Fyarro (sirolimus albumin-bound).
- Contains customary biotech manufacturing terms; full agreement to be filed later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/0001193125-23-012507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/d611917d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-012507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer